

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Memorial Healthcare 2. 826 W King St. Owosso, MI 48867		In accordance with letter dated December 01, 2017. 3. License number: 21-11475-01 is amended in its entirety to read as follows:	4. Expiration Date: December 31, 2024 5. Docket No.: 030-02100 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Iodine-125 permitted by 10 CFR 35.400 E. Palladium-103 permitted by 10 CFR 35.400	7. Chemical and/or physical form A. Any B. Any C. Any D. Sealed Sources (Medi-Physics, Inc., Model 6711 (OncoSeed)) E. Sealed Sources (Theragenics Corporation, Model 200 (TheraSeed))	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 300 millicuries total D. 150 millicuries total E. 400 millicuries total	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For any manual brachytherapy procedure permitted by 10 CFR 35.400. E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-11475-01Docket or Reference Number
030-02100

Amendment No. 41

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 826 W King St., Owosso, Michigan, 48867.
11. The Radiation Safety Officer (RSO) for this license is AppaRao Mukkamala, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|--|---|
| Jack L. Nettleton, M.D. | 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less) and 35.400 |
| Sherrie M. Brooks, D.O. | 10 CFR 35.100 and 35.200 |
| Hesham M. El Gayar, M.D. | 10 CFR 35.100, 35.200, 35.300, and 35.400 |
| AppaRao Mukkamala, M.D. | 10 CFR 35.100, 35.200, 35.300, and 35.400 |
| P.B. Lauber, M.D. | 10 CFR 35.100, 35.200, and 35.300 |
| Ahmed M. Akl, M.D. | 10 CFR 35.300 and 35.400 |
| M. Rao Tummala, M.D. | 10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less) |
| Dindi D. Reddy, M.D. | 10 CFR 35.100 and 35.200 |
| Anant Patel, M.D. | 10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131) |
| Gagandeep Singh, M.D. | 10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131) |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-11475-01Docket or Reference Number
030-02100

Amendment No. 41

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated May 29, 2014 (ML14168A580)
- B. Letter dated November 12, 2014 (ML14317A765)
- C. Letter dated January 14, 2015 (ML15030A469)
- D. Letter dated December 1, 2017 (ML17349A834)

Date: March 1, 2018

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: Sara A. ForsterSara A. Forster
Region 3